Crossroad Venture Capital Fund

Crossroad Venture Capital Fund (Crossroad FCP) is a Luxembourg-based open-ended venture capital fund whose units are listed on the Luxembourg Stock Exchange, making it one of the few publicly traded early-stage venture vehicles in Europe. Founded in 2010 and backed by the Generali Insurance Group as its primary LP, the fund focuses exclusively on early-stage Israeli companies with unique intellectual property, exceptional management teams, and strong potential for market penetration and growth. Generali's permanent capital backing gives Crossroad a longer investment horizon than typical closed-end funds. The fund invests at pre-seed and seed stages, deploying $1 million to $10 million per company across medical devices, information and communications technology, renewable energy, biotechnology, and pharmaceuticals. With 15 investments spanning healthtech, AI, biotech, energy, and pharma, Crossroad covers Israel's strongest technology sectors. The fund leverages Generali's multinational network and strategic relationships to add value beyond capital — particularly in commercialization support for Israeli companies seeking to scale into European markets. Crossroad's structure as a listed, open-ended fund backed by one of Europe's largest insurance groups differentiates it meaningfully in the Israeli deep tech ecosystem. This combination of stock exchange liquidity, permanent capital, and a marquee corporate LP provides portfolio companies with a credible long-term institutional partner at the earliest stages of company development.